Navigation Links
Providence-Based NABsys, Inc., Announces $4 Million Equity Financing
Date:5/5/2009

PROVIDENCE, R.I., May 5 /PRNewswire/ -- NABsys, Inc., the pioneer in electronic, solid-state DNA sequencing, announced today that it has closed a $4 million equity round led by Point Judith Capital. Slater Technology Fund and other previous investors also participated in the round. The proceeds will be used to further develop NABsys' proprietary DNA sequencing platform.

"The NABsys approach combines the advantages of electronic detection, solid-state fabrication, and the ability to directly obtain long-range sequence information," said Point Judith Capital General Partner Gina Raimondo. "We believe this will be a game-changing technology in the field of genomics." Dr. Raimondo will be joining the NABsys Board of Directors.

Historically, DNA sequencing technologies have used optical detection, have depended on enzymes known as polymerases, and have not been compatible with solid-state fabrication technology. As a result, whole-genome DNA sequencing has remained far too expensive, slow, and inaccurate to be used in clinical care. NABsys' electronic, solid-state approach overcomes these limitations.

"The technological advantages that the NABsys platform enjoys, namely electronic detection, the use of all solid-state materials, lack of dependence on a polymerase, inherent error checking, and long-range sequence information, will allow the technology to offer clinically relevant cost, speed, and accuracy parameters for whole-genome sequencing," said NABsys President and CEO Barrett Bready, M.D.

Based on technology developed at and licensed from Brown University, the NABsys DNA sequencing platform combines physical and biochemical methods. It detects electronically the positions of hybridized DNA probes and then uses highly developed algorithms to accurately reconstruct the DNA sequence.

About NABsys, Inc.

NABsys is a life sciences company working at the intersection of physics, biology, and computer science to develop its proprietary electronic, solid-state DNA sequencing platform. NABsys is one of five companies to receive a "$1000 Genome" award from the National Human Genome Research Institute of the National Institutes of Health. For more information, please visit www.nabsys.com

About Point Judith Capital

Point Judith Capital is a leading early-stage venture capital firm partnering with outstanding entrepreneurs building world class healthcare, internet, and technology companies. Point Judith Capital has a strategic partnership with Tudor Investment Corporation, a premier, global alternative asset management firm.


'/>"/>
SOURCE NABsys, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
2. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
5. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
6. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
7. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
8. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
9. Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company
10. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
11. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):